first pregnancy appears to the accumulation of risk, obesity and certain types of breast cancer

In the age of first pregnancy appears to the accumulation of risk, obesity and certain types of breast cancer. A groundbreaking study by University of Wisconsin Medical School and public health leaders said they have children or no life along with obesity, causing the risk of breast cancer. In the conception and the link between age and breast cancer may be strong women who never had children or who waited until 30 or later have a child.

The study consists of about 1912 to 1986 women born in 50000, of which 29,000 were diagnosed with breast cancer. Those aged 30 or over, while the pregnancy first child or a child has never been reported in the elevation of 2.5% of lobular breast cancer. Breast cancer, is clearly the most common form of breast cancer, but the lobular and mixed ductal, lobular breast cancer cases in the 20th century, the rapid increase in 90 years and accounts for 20 percent of all breast cancer events.

"Our study found that children who never or was at or after 30 children had a three times greater development of lobular breast cancer risk in obese women. Has been strong evidence that obesity, sedentary lifestyle and alcohol use can in breast cancer risk factors. These are all risk factors, women can change, "highlighted the cancer center from the Polly Newcomb.



Since lobular breast cancer lobular breast where it started, it may be difficult to find a breast X-rays. Ductal carcinoma, on the other hand, began to pipe lining in a milk and more easy to detect. Authors suggest that postmenopausal hormone replacement and the risk of lobular breast cancer linked.

The study, published in the journal Cancer.

Bone drug cuts breast cancer death rate

A drug designed to treat bone thinning has been found to prevent secondary tumours in women who have had breast cancer and to increase their survival rates.
The study of more than 1,000 women who had received surgery for primary breast cancer found that giving them the drug, bisphosphonate clodronate, for two years reduced the occurrence of bone cancer by 56 per cent.
The number of deaths from the original breast cancers was reduced by 23 per cent. The researchers also detected a trend towards a reduction in cancers of major organs although these findings were not statistically significant.
However, they could be important for other cancers that can lead to cancer in bones, including prostate cancer.
Prof Trevor Powles, head of the breast unit at the Royal Marsden Hospital, London, led the study. He said yesterday: "There were little or few side effects from the treatment.
"So much is now happening in breast cancer that is positive and I am very glad to be involved. Several other studies have already started following our findings."
He said that while the researchers had hoped to see a reduction in the occurrence of cancer of the bones, to which breast cancer commonly spreads, the reduction in the death rate was unexpected.
"The findings of this study are encouraging for breast cancer patients and may pave the way to more routine use of clodrinate or other bisphophonates in the prevention of bone metastases," he said.
Clodrinate, tradename, Bonefos, was first licensed in 1985 to treat bone thinning.
The women in the study, published in the Journal of Clinical Oncology this month, had all had surgery for primary breast cancer which had shown no sign of spreading to their bones. They were also being treated with chemotherapy and tamoxifen.